同和藥業(300636.SZ):一季度CMO/CDMO銷售收入為4506萬元 同比增長132.9%、毛利率超40%
格隆匯4月26日丨同和藥業(300636.SZ)於2023年4月24日接受特定對象調研,就“CMO/CDMO(定製)業務經營情況”,公司表示,CMO/CDMO銷售收入:2022年收入1.1086億元,同比增長22.5%;2023年一季度銷售收入為4506萬元,同比增長132.9%。2022年、2023年一季度CMO/CDMO的毛利率均超過40%。近年公司改變在CMO/CDMO項目上的保守態度,新增項目有所增多,但報吿期內的銷售增長主要還是由於老項目的貢獻。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.